



## **Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients**

December 9, 2010

Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients Phase 2 data to be presented at 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology